Xencor (XNCR) Interest Expenses (2013 - 2026)
Xencor (XNCR) posted quarterly Interest Expenses of $92.0 million for Q1 2026, up 962.15% year-over-year from $8.7 million in Q1 2025, and up 3617.08% quarter-over-quarter from $2.5 million in Q4 2025.
Analysis
Xencor (XNCR) Interest Expenses (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Interest Expenses for 14 consecutive years, with $92.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 962.15% year-over-year to $92.0 million; the TTM figure through Mar 2026 stood at $92.0 million (up 369.4% YoY), while the FY2025 annual figure was $94.6 million, down 58.37% from the prior year.
- Interest Expenses rose to $92.0 million in Q1 2026 per XNCR's latest filing, from $2.5 million in the prior quarter.
- Across five years, Interest Expenses topped out at $103.5 million in Q3 2024 and bottomed at -$2.6 million in Q4 2024.
- Historically, Interest Expenses has averaged $33.1 million across 5 years, with a median of $9.7 million in 2024.
- On a YoY basis, Interest Expenses climbed as much as 1236.46% in 2024 and fell as far as 167.64% in 2024.
- Xencor's Interest Expenses stood at $2.9 million in 2022, then jumped by 36.97% to $3.9 million in 2023, then slumped by 167.64% to -$2.6 million in 2024, then surged by 193.58% to $2.5 million in 2025, then soared by 3617.08% to $92.0 million in 2026.
- Business Quant data shows XNCR's Interest Expenses at $92.0 million in Q1 2026, $2.5 million in Q4 2025, and $97.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Xencor | 2.02 Bn | 1.64 Bn | - | 7.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.35 Mn |
| Mar 31, 2026 | 4.70 Mn |
| Dec 31, 2025 | 7.35 Mn |
| Sep 30, 2025 | 7.67 Mn |
| Jun 30, 2025 | 8.24 Mn |
| Mar 31, 2025 | 8.67 Mn |
| Dec 31, 2024 | 8.66 Mn |
| Sep 30, 2024 | 9.03 Mn |
| Jun 30, 2024 | 9.28 Mn |
| Mar 31, 2024 | 9.68 Mn |
| Dec 31, 2023 | 6.16 Mn |
| Sep 30, 2023 | 7,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Mar 31, 2023 | 7,000.00 |
| Jun 30, 2018 | 3,000.00 |
| Mar 31, 2018 | 4,000.00 |
| Dec 31, 2017 | 5,000.00 |
| Sep 30, 2017 | 3,000.00 |
| Jun 30, 2017 | 3,000.00 |
| Mar 31, 2017 | 3,000.00 |